SCHEMBL334480

SCHEMBL334480

C=CC1Cc2ccccc2O1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.49
MAOB P27338 7/20 0.41
MAOA P21397 6/20 0.41
AOC2 O75106 5/20 0.41
DAO P14920 1/20 0.41
CHRM2 P08172 2/20 0.38
CHRM4 P08173 2/20 0.38
CHRM5 P08912 2/20 0.38
CHRM1 P11229 2/20 0.38
CHRM3 P20309 2/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
NISCH Q9Y2I1 1/20 0.36
PRCP P42785 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
AR P10275 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12060988 1.00 HRH3 (0.49) HRH3MAOBMAOAAOC2DAO
SCHEMBL30142986 1.00 HRH3 (0.49) HRH3MAOBMAOAAOC2DAO
SCHEMBL1568046 0.81 CA2 (0.41) HRH3NISCH
SCHEMBL30513665 0.81 CA2 (0.41) HRH3NISCH
SCHEMBL6028552 0.81 CA2 (0.41) HRH3NISCH
SCHEMBL9113367 0.81 HRH3 (0.40) HRH3MAOBMAOAAOC2DAO
SCHEMBL451210 0.80 MAOB (0.41) HRH3MAOBMAOAAOC2DAO
SCHEMBL434337 0.80 MAOA (0.41) HRH3MAOBMAOAAOC2DAO
SCHEMBL28842254 0.80 MAOB (0.49) HRH3MAOBMAOAAOC2DAO
SCHEMBL6209606 0.80 MAOB (0.41) HRH3MAOBMAOAAOC2DAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097738-B2 Ruthenium (II) catalysts for use in stereoselective cyclopropanations VANDA PHARMACEUTICALS INC. (US) 2012-01-17 US claimed
US-7754902-B2 Ruthenium(II) catalysts for use in stereoselective cyclopropanations VANDA PHARMACEUTICALS, INC. (US) 2010-07-13 US claimed
CN-110330982-A A kind of material of the soil sanitation reparation of adjustable function 权冉(银川)科技有限公司 2019-10-15 CN disclosed
CN-106543119-B Preparation method of optically pure tasimelteon 浙江工业大学 2019-07-26 CN disclosed
CN-109748759-A Water treatment material and soil purifying, repairing and fertilizing material and preparation and use method thereof 权冉(银川)科技有限公司 2019-05-14 CN disclosed
US-9822103-B2 Inhibitors of lysine methyl transferase BRISTOL-MYERS SQUIBB COMPANY (US) 2017-11-21 US disclosed
CN-106543119-A Preparation method of optically pure tasimelteon 浙江工业大学 2017-03-29 CN disclosed
US-20160297805-A1 INHIBITORS OF LYSINE METHYL TRANSFERASE BRISTOL MYERS SQUIBB CO (US) 2016-10-13 US disclosed
WO-2015077194-A1 INHIBITORS OF LYSINE METHYL TRANSFERASE BRISTOL-MYERS SQUIBB COMPANY (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297805-A1 INHIBITORS OF LYSINE METHYL TRANSFERASE EZH2, DOT1L, EHMT1 HRH3 766/4885MAOB 2894/4885MAOA 2913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.